Company intelligence / Profile preview

Saranas

Houston, Texas, United Statesbairdcapital.com ↗

Ownership: Private
Development stage: Other

Overview

The Early Bird Bleed Monitoring System demonstrated a significant reduction in severe access-site bleeds in high-risk PCI patients using mechanical circulatory support—66.3% reduction compared to historical controls. First-in-human studies showed nearly perfect agreement with CT scan for bleed detection and achieved FDA De Novo clearance in 2019. SAFE-MCS trial completed enrollment of over 180 patients across multiple US centers.

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapy (bleed monitoring system)
Industry: Physiological Monitoring

Partnerships

Not specifically disclosed; pursuing strategic business partnerships as part of commercialization strategy.

Beyond the preview

Go deeper on Saranas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saranas.

Explore the full profile